Long-term survival analysis of masitinib in amyotrophic lateral sclerosis

BACKGROUND: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora, Jesus S., Bradley, Walter G., Chaverri, Delia, Hernández-Barral, María, Mascias, Javier, Gamez, Josep, Gargiulo-Monachelli, Gisella M., Moussy, Alain, Mansfield, Colin D., Hermine, Olivier, Ludolph, Albert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388186/
https://www.ncbi.nlm.nih.gov/pubmed/34457038
http://dx.doi.org/10.1177/17562864211030365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388186/
https://www.ncbi.nlm.nih.gov/pubmed/34457038
http://dx.doi.org/10.1177/17562864211030365

Ejemplares similares